Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01424878 · ClinicalTrials.gov registry record

Study of Molecular Pathways in Medullary Thyroid Carcinoma and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients

A clinical trial of Medullary Thyroid Carcinoma and Multiple Endocrine Neoplasia Type 2, sponsored by National Cancer Institute (NCI).

Completed
Registry status
150
Enrollment target
1
Study location

NCT01424878: Completed study of Medullary Thyroid Carcinoma and Multiple Endocrine Neoplasia Type 2, sponsored by National Cancer Institute (NCI).

NCT01424878 is a study of Medullary Thyroid Carcinoma and Multiple Endocrine Neoplasia Type 2 that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 150 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01424878, a study of Medullary Thyroid Carcinoma and Multiple Endocrine Neoplasia Type 2, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
150 participants
Enrollment target
1
Study location

Study Summary

Background: Medullary thyroid carcinoma (MTC) is a rare malignancy, occurring either as a sporadic disease (75% of cases), or in a hereditary pattern as multiple endocrine neoplasia (MEN) type 2 (MEN2A or MEN2B) or familial medullary thyroid carcinoma (FMTC). The MTC arises from the neural crest C-cells and in hereditary cases the first pathological disorder is C-cell hyperplasia (CCH) Most patients with MTC have advanced disease at the time of diagnosis. Chemotherapy and external beam radiotherapy have been minimally effective. Molecular targeted therapeutics (MTTs) and other receptor kinases in patients with advanced MTC have demonstrated activity. Despite some clinical responses, the collection of tumor tissues and autologous normal tissues has been virtually non-existent. Thus, laboratory studies defining affected molecular targets and downstream pathways, and molecular data providing direction for future clinical trials has yet to occur. Data from molecular studies of tumor tissue of hereditary or sporadic MTC patients will assist in predicting clinical behavior and the biology of MTC in predicting response to a given MTT, and in designing combination clinical trials. Objectives: Clarify how normal molecular pathways are altered by mutations in the RET protooncogene. Including additional genetic mutations and unidentified chromosomal translocations. Correlate results from molecular analyses of MTC tissue with patient s clinical course. Define how the molecular and clinical data will be useful in designing targeted therapy for patients with MTC. Eligibility: Patients must have confirmed diagnosis of C-cell hyperplasia, primary MTC, or metastatic MTC with archived pathology specimens available at Washington University. Design: Paraffin blocks of MTC tissues from archival samples at Washington University Department of Pathology will be selected. H\&E slide from selected tissue blocks will be examined for molecular study suitability. Necessary tissue

Study Locations (1)

Maryland

  • National Cancer Institute (NCI), 9000 Rockville Pike - Bethesda

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2010-07-05
Est. Completion 2014-02-12
National Cancer Institute (NCI)

3,257 total trials

What the finished NCT01424878 record still lists

NCT01424878 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap.

The record links to 2 conditions, with Medullary Thyroid Carcinoma appearing as the primary indexed condition, and to 0 interventions.

NCT01424878 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT01424878 about?

NCT01424878 is a clinical study titled "Study of Molecular Pathways in Medullary Thyroid Carcinoma and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients". Background: Medullary thyroid carcinoma (MTC) is a rare malignancy, occurring either as a sporadic disease (75% of cases), or in a hereditary pattern as multiple endocrine neoplasia (MEN) type 2 (MEN2A or MEN2B) or familial medullary thyroid carcinoma (FMTC). The MTC arises from the neural crest C-...

What is the current status of trial NCT01424878?

This trial is currently completed. The enrollment target is 150 participants. The study started on 2010-07-05. Estimated completion is 2014-02-12.

What conditions does trial NCT01424878 study?

This clinical trial studies the following conditions: Medullary Thyroid Carcinoma, Multiple Endocrine Neoplasia Type 2.

Who is sponsoring clinical trial NCT01424878?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01424878 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00412594 · 150 participants · Phase 2

    Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

  • NCT01484730 · 150 participants

    A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion

  • NCT01985919 · 150 participants

    Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples

  • NCT02016248 · 150 participants · NA

    SBRT Boost for Unfavorable Prostate Cancer'

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT01424878, the US trial registry maintained by the National Library of Medicine. NCT01424878 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.